Press Release Details
Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
- Conference Call and Webcast Today,
Conference Call and Webcast Details
Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 888-243-4451 or 412-542-4135 and ask to join the
A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 877-344-7529 or 412-317-0088 and provide Conference ID 8080876.
Selected Recent Events
-
Published results from a Phase 2 clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency in the
New England Journal of Medicine (NEJM) and presented in an oral presentation at The International Liver Congress™ 2022 - The Annual Meeting of theEuropean Association for the Study of the Liver (EASL). Key results included the following:- Fibrosis regression observed in 58% (7 of 12) of patients receiving 200 mg fazirsiran
- Median reduction of 83% of Z-AAT accumulation in the liver
- Reduction of 69% in histologic globule burden
- Substantial and sustained improvements in clinically relevant biomarkers of liver health
-
Hosted a pulmonary research & development (R&D) Day in
New York City to discuss the emerging pipeline of pulmonary targeted RNAi therapeutic candidates that leverage the company’s proprietary Targeted RNAi Molecule (TRIM™) platform -
Initiated Phase 1/2a clinical studies for two new investigational medicines designed to treat various muco-obstructive and inflammatory pulmonary conditions
- ARO-MUC5AC, an investigational RNAi therapeutic designed to inhibit the production of mucin 5AC (MUC5AC)
- ARO-RAGE, an investigational RNAi therapeutic designed to inhibit the production of Receptor for Advanced Glycation End products (RAGE)
-
Initiated the Phase 2
GATEWAY clinical study of ARO-ANG3, Arrowhead’s investigational medicine designed to silence the hepatic expression of angiopoietin-like protein 3 (ANGPTL3), in patients with homozygous familial hypercholesterolemia (HoFH) -
Strengthened the management team with the hiring of
Tracie Oliver as chief commercial officer and promotion of Patrick O’Brien to chief operating officer -
Formed a joint venture, Visirna Therapeutics, with
Vivo Capital to expand the reach of innovative medicines inGreater China -
Broke ground on construction of a new drug manufacturing facility and announced awards of up to
$18.5 million in tax incentives from the city ofVerona and theWisconsin Economic Development Corporation
Selected Fiscal 2022 Third Quarter Financial Results
|
CONSOLIDATED CONDENSED FINANCIAL INFORMATION (unaudited) (in thousands, except per share amounts) |
|||||||||||||||
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
OPERATING SUMMARY |
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
|
REVENUE |
$ |
32,412 |
|
|
$ |
45,891 |
|
|
$ |
211,656 |
|
|
$ |
100,004 |
|
|
OPERATING EXPENSES |
|
|
|
|
|
|
|
||||||||
|
Research and development |
|
72,180 |
|
|
|
59,325 |
|
|
|
213,930 |
|
|
|
140,576 |
|
|
General and administrative expenses |
|
33,141 |
|
|
|
18,434 |
|
|
|
92,403 |
|
|
|
43,581 |
|
|
TOTAL OPERATING EXPENSES |
|
105,321 |
|
|
|
77,759 |
|
|
|
306,333 |
|
|
|
184,157 |
|
|
OPERATING INCOME (LOSS) |
|
(72,909 |
) |
|
|
(31,868 |
) |
|
|
(94,677 |
) |
|
|
(84,153 |
) |
|
OTHER INCOME/(EXPENSE) |
|
863 |
|
|
|
1,944 |
|
|
|
4,125 |
|
|
|
6,679 |
|
|
NET INCOME (LOSS) |
$ |
(72,046 |
) |
|
$ |
(29,924 |
) |
|
$ |
(90,552 |
) |
|
$ |
(77,474 |
) |
|
|
|
|
|
|
|
|
|
||||||||
|
NET INCOME (LOSS) PER SHARE (DILUTED) |
$ |
(0.68 |
) |
|
$ |
(0.29 |
) |
|
$ |
(0.86 |
) |
|
$ |
(0.75 |
) |
|
WEIGHTED AVERAGE SHARES OUTSTANDING (DILUTED) |
|
105,753 |
|
|
|
104,099 |
|
|
|
105,273 |
|
|
|
103,569 |
|
|
|
|
|
|||
|
FINANCIAL POSITION SUMMARY |
|
|
|
||
|
CASH AND CASH EQUIVALENTS |
$ |
139,439 |
|
$ |
184,434 |
|
SHORT-TERM INVESTMENTS AND MARKETABLE SECURITIES |
|
277,057 |
|
|
183,355 |
|
|
|
165,920 |
|
|
245,595 |
|
TOTAL CASH RESOURCES (CASH AND INVESTMENTS) |
|
582,416 |
|
|
613,384 |
|
OTHER ASSETS |
|
169,366 |
|
|
96,764 |
|
TOTAL ASSETS |
$ |
751,782 |
|
$ |
710,148 |
|
TOTAL CURRENT DEFERRED REVENUE |
|
84,288 |
|
|
111,055 |
|
TOTAL LONG-TERM DEFERRED REVENUE |
|
71,162 |
|
|
131,495 |
|
OTHER LIABILITIES |
|
122,155 |
|
|
58,776 |
|
TOTAL LIABILITIES |
|
277,605 |
|
|
301,326 |
|
TOTAL STOCKHOLDERS' EQUITY |
|
474,177 |
|
|
408,822 |
|
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
$ |
751,782 |
|
$ |
710,148 |
|
|
|
|
|
||
|
SHARES OUTSTANDING |
|
105,795 |
|
|
104,327 |
About
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” or “continue” are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005918/en/
626-304-3400
ir@arrowheadpharma.com
Investors:
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com
Media:
646-751-4361
jo@lifescicomms.com
www.lifescicommunications.com
Source: